Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2

Speer, Claudius; Benning, Louise; Töllner, Maximilian; Nußhag, Christian; Kälble, Florian; Reichel, Paula; Schaier, Matthias; Bartenschlager, Marie; Schnitzler, Paul; Zeier, Martin; Süsal, Caner; Morath, Christian; Bartenschlager, Ralf

doi:10.1016/j.kint.2021.07.002

Cited by 24 publications

(42 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies assessed anti-SARS-CoV-2 immunity through an immunoassay to detect antibodies targeted at the spike protein, including some targeting specifically the receptor-binding domain (RBD) of the spike protein. Thirty studies reported neutralization assay results in addition to anti-SARS-CoV-2 antibody assays [ 34 , 37 , 41 , 48 , 51 , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] ]. Thirty-one studies provided data on cellular immunity [ 17 , 21 , 22 , 34 , 37 , 41 , 45 , 46 , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , 72 , [74] , [75] , [76] , [77] , [79] , [80] , [81] , [82] , [83] , [84] ].…”

Section: Resultsmentioning

confidence: 99%

“…Thirty-three studies reported immunogenicity in 6302 patients on dialysis ( Table S4 ) [ [15] , [16] , [17] , 21 , 31 , 38 , 44 , [62] , [63] , [64] , 74 , 78 , 80 , [114] , [115] , [116] , [117] , [118] , [119] , [120] , [121] , [122] , [123] , [124] , [125] , [126] , [127] , [128] , [129] , [130] , [131] , [132] , [133] , [134] ]. Non-responder rates ranged from 2% to 30% ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…found a high non-response rate at 27% (22/80), at least partially explained by the choice of a higher cut-off (29 U/mL) than the one provided by the manufacturer of the serological assay [ 118 , 135 ]. Fifteen studies included a control group ( n = 779 overall), in which all but nine participants developed post-vaccine antibodies [ 17 , 21 , 63 , 74 , 78 , 80 , 116 , 118 , 120 , 121 , 124 , 126 , 128 , 131 , 134 ]. Speer et al.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

Galmiche

Ngũyen

Tartour

et al. 2022

Clinical Microbiology and Infection

131

115

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

Galmiche

Ngũyen

Tartour

et al. 2022

Clinical Microbiology and Infection

131

115

View full text Add to dashboard Cite

“…These values are comparable with recently published data by Stumpf et al, where 76% of dialysis patients had detectable IgG- and IgA-S1 antibodies 8 weeks after the first vaccination with either BNT162b2 or mRNA-1273 vaccines [ 25 ]. However, we recently showed that even if SARS-CoV-2 specific antibodies are detectable by commercially available tests, neutralization of VOCs may be insufficient to protect from (re-)infection, especially in individuals with low peak neutralizing antibodies [ 14 ]. Data on VOCs neutralization in high-risk cohorts with low peak and rapid waning neutralizing antibody levels are urgently needed to enable the assessment of breakthrough infection risk.…”

Section: Discussionmentioning

confidence: 99%

“…Sustained high levels of neutralizing antibodies are a prerequisite for long-term protection against (re-)infection and severe COVID-19 [ 13 ]. Therefore, immune-compromised populations such as dialysis patients mounting lower neutralizing antibodies might become more sensitive to VOCs such as B.1.351 (beta variant) or B.1.617.2 (delta variant) [ 14 ]. Data on the longevity of vaccine-induced humoral responses in hemodialysis and peritoneal dialysis patients are urgently needed to enable individualized booster vaccinations and ultimately protect these high-risk groups permanently from severe COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks

et al. 2021

Self Cite

View full text Add to dashboard Cite

It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed.

show abstract

Live‐virus serum neutralization after bivalent SARS‐CoV‐2 mRNA vaccination in hemodialysis patients

Benning,

Bartenschlager,

Kim

et al. 2023

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

The development of bivalent booster vaccines addresses the ongoing evolution of the emerging B.1.1.529 (omicron) variant subtypes that are known to escape vaccine‐induced neutralizing antibody response. Little is known about the immunogenicity and reactogenicity of bivalent mRNA vaccines in hemodialysis patients with impaired vaccine response. In this prospective, observational cohort study, we analyzed SARS‐CoV‐2 anti‐S1 IgG, surrogate neutralizing antibodies (SNA), and live‐virus neutralization against the SARS‐CoV‐2 wildtype and the BA.5 variant in 42 hemodialysis patients with and without prior SARS‐CoV‐2 infection before and after an additional fifth bivalent vaccine dose. Anti‐S1 IgG and SNA were significantly higher in hemodialysis patients with prior infection than in patients without infection (p < 0.001 and p < 0.01, respectively). In patients without prior infection, both antibody levels increased, and live‐virus neutralizing antibodies against the wildtype and the BA.5 variant were correspondingly significantly higher after bivalent booster vaccination (p < 0.001 for both). Conversely, in patients with prior infection, anti‐S1 IgG and SNA did not alter significantly, and bivalent booster vaccination did not induce additional humoral immune response against the SARS‐CoV‐2 wildtype and the BA.5 variant. Thus, bivalent mRNA vaccines might increase humoral responses in hemodialysis patients without prior infection. Larger clinical trials are needed to help guide vaccination strategies in these immunocompromised individuals.

show abstract

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2

Cited by 24 publications

References 4 publications

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks

Live‐virus serum neutralization after bivalent SARS‐CoV‐2 mRNA vaccination in hemodialysis patients

Contact Info

Product

Resources

About